Merck drug combination reduces lung cancer progression risk in trial
A Merck antibody-drug conjugate combined with Keytruda lowered the risk of tumor progression by 65 percent in a Phase 3 lung cancer study. The results come from an abstract released ahead of the American Society of Clinical Oncology meeting.
thehindu.comMerck reported that its antibody-drug conjugate developed with a Chinese partner, when paired with Keytruda, sharply outperformed Keytruda alone in a subset of lung cancer patients.
Data showed the paired treatment delayed disease progression more effectively than Keytruda monotherapy.
A closely watched experimental Parkinson’s drug failed to meet its primary endpoint in a key clinical trial. The outcome was reported on May 21. Separately, a longevity startup backed by Sam Altman raised additional funds, reaching a valuation of $1.8 billion.
Key Facts
Story Timeline
2 events- May 22, 2026
Merck reported Phase 3 results for its lung cancer drug combination.
1 source@statnews - May 21, 2026
Experimental Parkinson’s drug failed key clinical trial.
1 source@statnews
Potential Impact
- 01
Merck may seek regulatory approval for the drug combination based on trial data.
- 02
Investors may adjust positions in companies developing similar oncology treatments.
Transparency Panel
Related Stories
NprWHO Director Visits Congo as Ebola Outbreak Spreads
The head of the World Health Organization arrived in Kinshasa to support efforts against a rare Ebola strain. Health workers face equipment shortages, community distrust, and armed conflict in affected provinces.
medpagetoday.comFDA Panel Recommends XFG Variant for Fall Covid Shots
Replimune will submit an application to the FDA for the third time. Pfizer and Innovent Biologics reached a collaboration agreement valued at up to $10.5 billion.
Benzinga Publishes Article on Biotech Stocks During Pandemic Recovery
Benzinga published an article titled 'Best Biotech Stocks Right Now' that addresses the sector's position during global recovery from the pandemic. The piece notes government institutions and professional traders are focusing on biotech companies for vaccine and booster developme…